These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34101779)

  • 1. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.
    Kellar D; Lockhart SN; Aisen P; Raman R; Rissman RA; Brewer J; Craft S
    J Prev Alzheimers Dis; 2021; 8(3):240-248. PubMed ID: 34101779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Craft S; Raman R; Chow TW; Rafii MS; Sun CK; Rissman RA; Donohue MC; Brewer JB; Jenkins C; Harless K; Gessert D; Aisen PS
    JAMA Neurol; 2020 Sep; 77(9):1099-1109. PubMed ID: 32568367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
    Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
    J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
    Craft S; Baker LD; Montine TJ; Minoshima S; Watson GS; Claxton A; Arbuckle M; Callaghan M; Tsai E; Plymate SR; Green PS; Leverenz J; Cross D; Gerton B
    Arch Neurol; 2012 Jan; 69(1):29-38. PubMed ID: 21911655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.
    Claxton A; Baker LD; Hanson A; Trittschuh EH; Cholerton B; Morgan A; Callaghan M; Arbuckle M; Behl C; Craft S
    J Alzheimers Dis; 2015; 44(3):897-906. PubMed ID: 25374101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease.
    Rosenbloom M; Barclay TR; Kashyap B; Hage L; O'Keefe LR; Svitak A; Pyle M; Frey W; Hanson LR
    Drugs Aging; 2021 May; 38(5):407-415. PubMed ID: 33719017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
    Lee JY; Lee H; Yoo HB; Choi JS; Jung HY; Yoon EJ; Kim H; Jung YH; Lee HY; Kim YK
    Neurotherapeutics; 2019 Apr; 16(2):394-403. PubMed ID: 30761509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease.
    Claxton A; Baker LD; Wilkinson CW; Trittschuh EH; Chapman D; Watson GS; Cholerton B; Plymate SR; Arbuckle M; Craft S
    J Alzheimers Dis; 2013; 35(4):789-97. PubMed ID: 23507773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional White Matter Hyperintensity Influences Grey Matter Atrophy in Mild Cognitive Impairment.
    Vipin A; Foo HJL; Lim JKW; Chander RJ; Yong TT; Ng ASL; Hameed S; Ting SKS; Zhou J; Kandiah N
    J Alzheimers Dis; 2018; 66(2):533-549. PubMed ID: 30320575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontal white matter hyperintensity predicts lower urinary tract dysfunction in older adults with amnestic mild cognitive impairment and Alzheimer's disease.
    Ogama N; Yoshida M; Nakai T; Niida S; Toba K; Sakurai T
    Geriatr Gerontol Int; 2016 Feb; 16(2):167-74. PubMed ID: 25613527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between small cerebral white matter lesions and cognitive function in patients with Alzheimer's disease and amnestic mild cognitive impairment.
    Makino T; Umegaki H; Suzuki Y; Yanagawa M; Nonogaki Z; Nakashima H; Kuzuya M
    Geriatr Gerontol Int; 2014 Oct; 14(4):819-26. PubMed ID: 24215176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Associations Between Serum Insulin-like Growth Factor-I, Brain White Matter Volumes, and Cognition in Mild Cognitive Impairment and Alzheimer's Disease.
    Horvath A; Quinlan P; Eckerström C; Åberg ND; Wallin A; Svensson J
    J Alzheimers Dis; 2024; 99(2):609-622. PubMed ID: 38701139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.
    Bilello M; Doshi J; Nabavizadeh SA; Toledo JB; Erus G; Xie SX; Trojanowski JQ; Han X; Davatzikos C
    J Alzheimers Dis; 2015; 48(4):987-94. PubMed ID: 26402108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial.
    Kellar D; Register T; Lockhart SN; Aisen P; Raman R; Rissman RA; Brewer J; Craft S
    Sci Rep; 2022 Jan; 12(1):1346. PubMed ID: 35079029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
    Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
    J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal Insulin for Alzheimer's Disease.
    Hallschmid M
    CNS Drugs; 2021 Jan; 35(1):21-37. PubMed ID: 33515428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
    Stein MS; Scherer SC; Ladd KS; Harrison LC
    J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.